 Phase clinical pharmacokinetic trial flavone acetic acid Flavone acetic acid synthetic benzopyrone derivative unknown mechanism action Thirty-eight patients men women week weeks weeks doses flavone acetic acid doses equal drug hour doses equal infusion period hours Treatment patients hydration treatment alkalization urine pH equal dose-limiting toxic effect hypotension Pharmacokinetic studies linear behavior patients Peak plasma levels micrograms/mL mean terminal half-life hours Immunologic monitoring patients transient increase and/or cells patients patient increase increase cell objective tumor responses trial recommended phase II dose schedule Further studies drug mechanism action immunologic properties